<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2018.8616</article-id>
<article-id pub-id-type="publisher-id">mmr-17-04-5764</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Lentivirus-mediated MDA7/IL24 expression inhibits the proliferation of hepatocellular carcinoma cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Ma</surname><given-names>Chao</given-names></name>
<xref rid="af1-mmr-17-04-5764" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Ling-Ling</given-names></name>
<xref rid="af1-mmr-17-04-5764" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Heng-Jun</given-names></name>
<xref rid="af1-mmr-17-04-5764" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Cui</surname><given-names>Jiu-Wei</given-names></name>
<xref rid="af1-mmr-17-04-5764" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Wei</given-names></name>
<xref rid="af1-mmr-17-04-5764" ref-type="aff"/></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Nan-Ya</given-names></name>
<xref rid="af1-mmr-17-04-5764" ref-type="aff"/>
<xref rid="c1-mmr-17-04-5764" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-mmr-17-04-5764">Oncology Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-17-04-5764"><italic>Correspondence to</italic>: Professor Nan-Ya Wang, Oncology Center, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin 130021, P.R. China, E-mail: <email>nanyawang@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub"><month>04</month><year>2018</year></pub-date>
<pub-date pub-type="epub"><day>16</day><month>02</month><year>2018</year></pub-date>
<volume>17</volume>
<issue>4</issue>
<fpage>5764</fpage>
<lpage>5773</lpage>
<history>
<date date-type="received"><day>26</day><month>04</month><year>2017</year></date>
<date date-type="accepted"><day>23</day><month>01</month><year>2018</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Ma et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>MDA7/IL24 is a member of the IL-10 gene family that functions as a cytokine. Notably, supra-physiological endogenous MDA7 levels have been indicated to suppress tumor growth and induce apoptosis in different cancer types. In the present study, MDA7 roles were investigated during the proliferation of hepatocellular carcinoma (HCC) cells and the molecular mechanisms underlying this process. A lentiviral vector expressing MDA7/IL24 (LV-MDA7/IL24) was constructed and used to infect HCC SMMC-7721 cells. The expression levels of <italic>MDA7/IL24</italic> in these cells were determined using RT-qPCR and western blot analysis. The effects of LV-MDA7/IL24 on cell proliferation were analyzed using MTT and colony formation assays. Furthermore, the influence of LV-MDA7/IL24 on cell apoptosis and cell cycle distribution were detected using flow cytometry. The underlying molecular mechanisms were investigated using microarray and western blot analysis. The expression of <italic>MDA7/IL24</italic> was confirmed to be significantly increased in the cells infected with LV-MDA7/IL24 compared with that the negative-control infected group. Lentivirus-mediated <italic>MDA7/IL24</italic> expression was found to inhibit HCC cell proliferation and colony formation, and it also induced cell arrest and apoptosis. Microarray analysis and western blotting results indicated that multiple cancer-associated pathways and oncogenes are regulated by MDA7/IL24, including cell cycle regulatory and apoptosis activation pathway. In conclusion, it was determined that MDA7/IL24 inhibits the proliferation and reduces the tumorigenicity of HCC cells by regulating cell cycle progression and inducing apoptosis, indicating that it may be used as a potential prognostic and therapeutic target in HCC.</p>
</abstract>
<kwd-group>
<kwd>IL24</kwd>
<kwd>lentivirus</kwd>
<kwd>hepatocellular carcinoma</kwd>
<kwd>apoptosis</kwd>
<kwd>cell cycle regulation</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third leading cause of cancer-related death worldwide. Despite the development of various therapies, the outcome for HCC patients remains poor. Generally, HCC patients have a 1-year survival rate of &#x003C;50&#x0025; and a 5-year survival rate of 10&#x0025; (<xref rid="b1-mmr-17-04-5764" ref-type="bibr">1</xref>). Annually, ~0.11 million people die from liver cancer in China, and the major reason for frequent HCC relapses are intrahepatic and distant metastases that develop after the curative surgical resection or transplantation (<xref rid="b2-mmr-17-04-5764" ref-type="bibr">2</xref>). Moreover, HCC is insensitive to chemotherapy and radiotherapy (<xref rid="b3-mmr-17-04-5764" ref-type="bibr">3</xref>). Therefore, novel HCC treatments such as gene therapy and molecular targeted therapy should be investigated (<xref rid="b4-mmr-17-04-5764" ref-type="bibr">4</xref>). As a multitarget anticancer drug, sorafenib has been approved for the treatment of HCC, but showed a very low success rate (<xref rid="b5-mmr-17-04-5764" ref-type="bibr">5</xref>). Gene therapy represents an alternative form of cancer treatment and was shown to have high efficiency, specificity, and few serious side effects (<xref rid="b4-mmr-17-04-5764" ref-type="bibr">4</xref>).</p>
<p>Melanoma differentiation-associated gene7/interleukin-24 (MDA7/IL24), a member of the IL10 cytokine family, was originally identified as a gene associated with the terminal differentiation and irreversible growth suppression of metastatic human melanoma cells (<xref rid="b6-mmr-17-04-5764" ref-type="bibr">6</xref>). MDA7/IL24 is considered to be secreted by the immune system and melanocytes alone (<xref rid="b7-mmr-17-04-5764" ref-type="bibr">7</xref>,<xref rid="b8-mmr-17-04-5764" ref-type="bibr">8</xref>). Several reports demonstrated the loss of <italic>MDA7/IL24</italic> expression during the progression of melanoma, and a significant inverse correlation between the loss of this gene and tumor invasion, suggesting that MDA7/IL24 may have anticancer effects (<xref rid="b6-mmr-17-04-5764" ref-type="bibr">6</xref>,<xref rid="b7-mmr-17-04-5764" ref-type="bibr">7</xref>,<xref rid="b9-mmr-17-04-5764" ref-type="bibr">9</xref>,<xref rid="b10-mmr-17-04-5764" ref-type="bibr">10</xref>). Additionally, our previous studies demonstrated that MDA7/IL24 has multiple anticancer functions, selectively inducing cancer cell apoptosis, but also showing immunomodulatory and antiangiogenic properties and strong antitumor bystander effects, which makes this molecule an ideal candidate for cancer gene therapy (<xref rid="b9-mmr-17-04-5764" ref-type="bibr">9</xref>&#x2013;<xref rid="b13-mmr-17-04-5764" ref-type="bibr">13</xref>).</p>
<p>We constructed MDA7/IL24-expressing lentiviral particles, and evaluated the effects of lentivirus-mediated MDA7/IL24 expression on HCC cell proliferation and colony-forming ability. Moreover, we explored the mechanisms underlying MDA7/IL24-mediated HCC regression (<xref rid="b14-mmr-17-04-5764" ref-type="bibr">14</xref>).</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Cell lines and culture conditions</title>
<p>HCC cell line SMMC-7721 was obtained from Cell Bank of Chinese Academy of Sciences (Shanghai, China), and maintained in Dulbecco&#x0027;s modified Eagle&#x0027;s medium (DMEM) supplemented with 10&#x0025; fetal bovine serum (FBS) and 100 U/ml of penicillin-streptomycin. The cells were incubated at 37&#x00B0;C in a humidified atmosphere with 5&#x0025; CO<sub>2</sub>. In addition, the cell line is not contaminated or mis-identified according to the Database of Cross-Contaminated or Misidentified Cell Lines.</p>
</sec>
<sec>
<title>Recombinant lentiviral particle construction and infection</title>
<p>We constructed <italic>MDA7/IL24</italic> gene expression plasmid, while an empty plasmid was used as a negative control. Following this, <italic>MDA7/IL24</italic>-expressing plasmid or the negative control plasmid, together with pHelper 1.0 and pHelper 2.0 (pVSVG-I and pCMV&#x0394;R 8.92 plasmids, respectively), were added to 293T cells with Lipofectamine 2000 (Invitrogen, Shanghai, China), according to the manufacturer&#x0027;s instructions. After 48 h of transfection, supernatants containing viral particles were collected and centrifuged (1,006 g, 20 min) to get rid of cell debris, and filtered through 0.45-&#x00B5;m polyvinylidene fluoride (PVDF) membranes. HCC cells were infected with <italic>MDA7/IL24</italic>-expressing lentiviral particles or the controls at the multiplicity of infection (MOI) of 20. The infected cells expressing green fluorescent protein (GFP) were observed under a fluorescence microscope (Micro Publisher 3.3RTV; Olympus, Tokyo, Japan). The cells were collected and total RNA was extracted to determine the efficiency of knockdown.</p>
</sec>
<sec>
<title>Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)</title>
<p>Total RNA was extracted and purified from SMMC-7721-infected cells, using Trizol reagent (Invitrogen) following the manufacturer&#x0027;s instructions. RT was performed to generate cDNA molecules, using M-MLV reverse transcriptase (Promega, Madison, WI, USA) and oligo(dT) primers (Sangon, Shanghai, China), following the manufacturers&#x0027; instructions. The expression of <italic>MDA7/IL24</italic> was determined by quantitative real-time (qRT-) PCR, using a PCR assay kit (TransGen Biotech, Beijing, China). Glyceraldehyde-3-phosphate dehydrogenase (<italic>GAPDH</italic>) cDNA was amplified as an internal reference. MDA7/IL24 primer set: Forward, 5&#x2032;-TTGCCTGGGTTTTACCCTGC-3&#x2032; and reverse, 5&#x2032;-AAGGCTTCCCACAGTTTCTGG-3&#x2032;; GAPDH forward, 5&#x2032;-TGACTTCAACAGCGACACCCA-3&#x2032; and reverse, 5&#x2032;-CACCCTGTTGCTGTAGCCAAA-3&#x2032;. PCR conditions included initial denaturation (95&#x00B0;C for 10 sec) and then 40 cycles of amplification (95&#x00B0;C for 15 sec and 55&#x00B0;C for 15 sec). <italic>MDA7/IL24</italic> relative expression was normalized to <italic>GAPDH</italic> levels by the 2<sup>&#x2212;&#x0394;&#x0394;Ct</sup> method (<xref rid="b15-mmr-17-04-5764" ref-type="bibr">15</xref>).</p>
</sec>
<sec>
<title>MTT assay</title>
<p>To investigate the effects of <italic>MDA7/IL24</italic> overexpression on cell viability, MTT assay was performed three times. SMMC-772 cells in the logarithmic growth phase were cultured for 24 h in 96-well plates (1&#x00D7;10<sup>5</sup> cells per well). After the infection, cells were incubated for additional 72 h. Mitochondrial function was evaluated by MTT colorimetric assay. Briefly, the medium was removed and a fresh medium containing 0.5 mg/ml MTT was added to each well. The cells were incubated at 37&#x00B0;C for 4 h. Following this, the supernatants were removed, 50 &#x00B5;l dimethylsulfoxide (DMSO) was added to each well, and samples were incubated for 30 min at 37&#x00B0;C with gentle shaking. Finally, absorbance was determined using a microplate reader at 490 nm. Cell viability was calculated as the ratio of the absorbance determined in the samples infected with the <italic>MDA7/IL24</italic> overexpression plasmid to that of the control group (untreated cells).</p>
</sec>
<sec>
<title>Colony formation assay</title>
<p>Infected and untreated SMMC-7721 cells were plated in six-well plates (200 cells/well) and cultured in a 5&#x0025; CO<sub>2</sub> incubator at 37&#x00B0;C for 14 days. The cells were washed twice with PBS and fixed in 4&#x0025; paraformaldehyde for 30 min. Cell colonies were stained with Giemsa dye (Chemicon, Temecula, CA, USA) for 20 min, and washed with double distilled water several times. Colony numbers were counted under a fluorescence microscope.</p>
</sec>
<sec>
<title>Cell cycle</title>
<p>Cells were cultured in 12-cell plates. After 5 days, the cells were collected and fixed with cold 70&#x0025; ethanol overnight at &#x2212;20&#x00B0;C, and then washed with cold PBS for one time. The fixed cells were treated with RNase and stained with propidium iodide (Sigma, St. Louis, MO, USA). The stained cells were analyzed by flow cytometer and ModFit LT software (Verity Software House, Topsham, ME, USA).</p>
</sec>
<sec>
<title>Cell apoptosis</title>
<p>Cell apoptosis was performed using Annexin V PE and 7-AAD apoptosis detection kit (BD Bioscience, San Diego, CA, USA) according to the manufacturer&#x0027;s instructions. Cells were collected after cultured 5 days, washed and resuspended with 1xbinding buffer. Then 5 &#x00B5;l Annexin V was added into 200 &#x00B5;l of the above cell suspension and incubated at room temperature in the dark for 15 min. After incubation, 5 &#x00B5;l 7-AAD was added the cell apoptosis was detected using the flow cytometer.</p>
</sec>
<sec>
<title>Microarray processing and analysis</title>
<p>Total RNA isolated from SMMC-7721 cells infected with either lentiviral vector expressing (LV-)MDA7/IL24 (n=3) or negative control lentivirus (n=3) was subjected to microarray analysis, to determine the global transcriptomic profile of each cell group, using Affymetrix human GeneChip according to the manufacturer&#x0027;s instructions. Microarray hybridization, washing, and staining were performed using the GeneChip Hybridization Wash and Stain kit (Affymetrix, Santa Clara, CA, USA). Arrays were then scanned using the GeneChip Scanner 3,000 to obtain raw data (Affymetrix). Significant differences in the expression of the analyzed genes between SMMC-7721 cells infected with either LV-MDA7/IL24 or negative control lentivirus were obtained based on P&#x003C;0.05.</p>
</sec>
<sec>
<title>Western blot analysis</title>
<p>Seventy-two h after the infection of SMMC-7721 cells with either LV-MDA7/IL24 or negative control lentivirus, the cells were collected and washed with PBS twice, and the lysis buffer was added to extract the cellular proteins. Afterwards, the lysates were centrifuged at 14,000 rpm at 4&#x00B0;C for 10 min and the supernatants were collected. BCA method was applied to determine the protein concentration. Twenty micrograms of protein sample obtained from the infected cells was separated by 10&#x0025; SDS-PAGE and then transferred to PVDF membrane. PVDF membranes were blocked at 4&#x00B0;C overnight with 5&#x0025; bovine serum albumin and incubated with monoclonal antibodies against B cell lymphoma protein-2 (BCL2; 1:500; ab692; Abcam, Cambridge, UK), Cyclin E (1:1,000; cat. no. 4132), p-ERK1/2 (1:800; cat. no. 4370), p-AKT (1:2,000; cat. no. 4060) and caspase-3 (1:1,000; cat. no. 9662; all CST Biological Reagents Co., Ltd., Shanghai, China). Thereafter, the horseradish peroxidase-conjugated secondary antibody we added for each corresponding primary antibody. The obtained blots were analyzed using enhanced chemiluminescence. GAPDH was detected on the same membrane as a loading control.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Student&#x0027;s t-test was performed for data analysis. Statistical analysis was performed using the SPSS version 22.0 software (SPSS, Chicago, IL, USA). All data were presented as mean &#x00B1; standard deviation (SD) of the results obtained in three independent experiments. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>LV-MDA7/IL24 infection induces MDA7/IL24 overexpression in SMMC-7721 cells</title>
<p>As presented in <xref rid="f1-mmr-17-04-5764" ref-type="fig">Fig. 1A</xref>, SMMC-7721 cells were shown to be GFP-positive following the infection with the lentiviral particles, indicating a high efficiency of the infection. Further analysis demonstrated a significant upregulation of <italic>MDA7/IL24</italic> expression in these cells (P&#x003C;0.001), compared with that in the cells infected with the negative control lentiviruses (<xref rid="f1-mmr-17-04-5764" ref-type="fig">Figs. 1B</xref> and <xref rid="f2-mmr-17-04-5764" ref-type="fig">2</xref>).</p>
</sec>
<sec>
<title>MDA7/IL24 overexpression inhibits SMMC-7721 cell proliferation and colony-forming ability</title>
<p>LV-MDA7/IL24-infected SMMC-7721 cells were shown to have a decreased growth rate, in comparison with the untreated and negative control-treated cells (P&#x003C;0.05). At day 5, we determined that the optical density at 490 nm (OD490) of LV-MDA7/IL24-infected cells was 0.921&#x00B1;0.013, while those of the negative control-infected and untreated cells were 0.988&#x00B1;0.007 and 1.094&#x00B1;0.007, respectively (<xref rid="f3-mmr-17-04-5764" ref-type="fig">Fig. 3</xref>). Colony-forming ability of SMMC-7721 cells was analyzed by crystal violet staining, and the number of cells per colony significantly decreased after LV-MDA7/IL24 infection (P&#x003C;0.05). Furthermore, we determined the number of colonies, and this number was found to decrease to 163&#x00B1;12 in samples overexpressing <italic>MDA7/IL24</italic>, compared with those in the untreated and negative control-treated cells (180&#x00B1;8 and 201&#x00B1;8, respectively) (<xref rid="f4-mmr-17-04-5764" ref-type="fig">Fig. 4</xref>).</p>
</sec>
<sec>
<title>MDA7/IL24 overexpression induces cell arrest and apoptosis</title>
<p>To demonstrate the reasons why MDA7/IL24 overexpression results in reduced cell viability, apoptosis and cell cycle of MDA7/IL24 positive and negative HCC cells were examined by flow cytometry. The results showed that MDA7/IL24 overexpression induced cell apoptosis (<xref rid="f5-mmr-17-04-5764" ref-type="fig">Fig. 5A and B</xref>) and elevated the percentage of G1 phage cells in SMMC-7721 cells (<xref rid="f5-mmr-17-04-5764" ref-type="fig">Fig. 5C</xref>).</p>
</sec>
<sec>
<title>MDA7/IL24 overexpression affects multiple cancer development pathways</title>
<p>To explore the molecular mechanisms underlying the anticancer effects of MDA7/IL24, we performed microarray analysis and gene expression profiling in cells infected with either LV-MDA7/IL24 or the negative control. A significant difference in the expression levels between these cells was observed for 43 genes, 20 with upregulated and 23 with downregulated expression (<xref rid="f6-mmr-17-04-5764" ref-type="fig">Fig. 6A</xref>). KEGG pathway analysis demonstrated that these genes were significantly enriched in three pathways, including cell cycle regulation, DNA synthesis and transcriptional and apoptosis (<xref rid="f6-mmr-17-04-5764" ref-type="fig">Fig. 6B</xref>). Additionally, we verified the differential expression of several key molecules involved in these two pathways by western blotting, which showed that the upregulation of <italic>MDA7/IL24</italic> induces the expression of caspase-3 and downregulates the expression of p-AKT, p-ERK1/2, CCNE2, and BCL2 (<xref rid="f7-mmr-17-04-5764" ref-type="fig">Figs. 7</xref>&#x2013;<xref rid="f10-mmr-17-04-5764" ref-type="fig">10</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Gene therapy has become a focus of current investigations aimed at improving HCC treatment (<xref rid="b16-mmr-17-04-5764" ref-type="bibr">16</xref>). MDA7/IL24 is a member of the IL10 cytokine family, and was shown to induce apoptosis in different cancers specifically, including HCC (<xref rid="b17-mmr-17-04-5764" ref-type="bibr">17</xref>), lung cancer (<xref rid="b18-mmr-17-04-5764" ref-type="bibr">18</xref>), melanoma (<xref rid="b19-mmr-17-04-5764" ref-type="bibr">19</xref>), breast cancer (<xref rid="b20-mmr-17-04-5764" ref-type="bibr">20</xref>), pancreatic cancer (<xref rid="b21-mmr-17-04-5764" ref-type="bibr">21</xref>), cervical cancer (<xref rid="b22-mmr-17-04-5764" ref-type="bibr">22</xref>), and prostate cancer (<xref rid="b23-mmr-17-04-5764" ref-type="bibr">23</xref>), but it does not affect normal cells (<xref rid="b24-mmr-17-04-5764" ref-type="bibr">24</xref>). Therefore, this gene may represent an ideal gene therapy target (<xref rid="b25-mmr-17-04-5764" ref-type="bibr">25</xref>). Additionally, MDA7/IL24 can induce the activation of immune system response aimed against cancer cells, and effectively inhibit neoplastic angiogenesis. It was demonstrated that the overexpression of this molecule and chemotherapy have synergistic effects (<xref rid="b26-mmr-17-04-5764" ref-type="bibr">26</xref>). However, <italic>MDA7/IL24</italic> overexpression mediated by lentiviruses has not been investigated previously.</p>
<p>Here, we constructed a <italic>LV-MDA7/IL24</italic>, and confirmed that the expression levels of this gene increase in SMMC-7721 cells infected with lentiviral particles carrying this vector. This demonstrated that the recombinant lentiviruses effectively promote the expression of <italic>MDA7/IL24</italic> in HCC cells. MTT and colony formation assays demonstrated that lentivirus-mediated <italic>MDA7/IL24</italic> expression markedly inhibits HCC cell proliferation. The number of cells and cell growth rate of LV-MDA7/IL24-infected cells were shown to be significantly decreased. In accordance with the results obtained in a previous study (<xref rid="b27-mmr-17-04-5764" ref-type="bibr">27</xref>), we demonstrated the anticancer effects of MDA7/IL24.</p>
<p>However, the molecular mechanisms underlying the effects of MDA7/IL24 on HCC cells remain unclear. We performed gene expression profiling of SMMC-7721 cells infected with LV-MDA7/IL24, demonstrating that many genes show significantly different expression between <italic>MDA7/IL24</italic>-overexpressing cells and the control cells. We further performed functional pathway analysis, and several pathways involving the differentially expressed genes were found to be involved in cancer development (<xref rid="b14-mmr-17-04-5764" ref-type="bibr">14</xref>), for example, G1/S checkpoint and G2/M DNA damage signaling pathway. These pathways are crucial for cell cycle regulation, DNA synthesis, and transcription. Previously, it was reported that MDA7/IL24 induces IL20/IL22 receptor-independent apoptosis by modulating multiple apoptotic signaling pathways such as mitochondrial pathway, MAPK, PKR, GADD pathways, and others (<xref rid="b28-mmr-17-04-5764" ref-type="bibr">28</xref>&#x2013;<xref rid="b30-mmr-17-04-5764" ref-type="bibr">30</xref>), and is involved in the accumulation of BAX and BCL2 (<xref rid="b31-mmr-17-04-5764" ref-type="bibr">31</xref>). The results of our western blot analysis showed that MDA7/IL24 induces the expression of caspase-3 and inhibits the expression of p-AKT, p-ERK1/2, CCNE2, and BCL2.</p>
<p>CCNE2 and p-ERK1/2 are molecules involved in cell cycle regulation, which can induce tumor progression by regulating cell cycle transition. Cyclin E2 is a member of cyclin E family, which forms cyclin E-CDK2 complex with CDK2 (<xref rid="b6-mmr-17-04-5764" ref-type="bibr">6</xref>). This complex promotes cell cycle progression by regulating G1/S phase transition, and the dysregulation of cyclin E2-CDK2 activity was shown to be involved in tumor development (<xref rid="b32-mmr-17-04-5764" ref-type="bibr">32</xref>). Moreover, the overexpression of cyclin E2 was shown to be associated with poor survival of breast cancer patients (<xref rid="b33-mmr-17-04-5764" ref-type="bibr">33</xref>). P-ERK1/2 is the activated form of ERK1/2, which plays an important role in cell proliferation by regulating cell cycle progression (<xref rid="b34-mmr-17-04-5764" ref-type="bibr">34</xref>). P-ERK1/2 was demonstrated to be a HCC prognostic marker, since increased p-ERK1/2 levels correlate with a decrease in the overall survival (<xref rid="b35-mmr-17-04-5764" ref-type="bibr">35</xref>). MDA7/IL24 overexpression induces CCNE2 and p-ERK1/2 downregulation, indicating that this molecule suppresses tumor progression by regulating cell cycle transition. Just as demonstrated by the experimental results, IL-24 overexpression induced G1 arrest in human HCC cells.</p>
<p>BCL2 is a 26-kDa oncoprotein, and its carcinogenic property is closely associated with the anti-apoptotic activity (<xref rid="b36-mmr-17-04-5764" ref-type="bibr">36</xref>). As a regulator of apoptosis, BCL2 may promote tumor cell survival and inhibit apoptosis through the regulation of mitochondrial membrane permeability and the induction of tumor angiogenesis (<xref rid="b37-mmr-17-04-5764" ref-type="bibr">37</xref>). BCL2 overexpression is related to tumor progression (<xref rid="b38-mmr-17-04-5764" ref-type="bibr">38</xref>). P-AKT, an active form of AKT, plays an important role in the inhibition of tumor cell apoptosis, promoting tumor cell proliferation and angiogenesis (<xref rid="b39-mmr-17-04-5764" ref-type="bibr">39</xref>). Many studies demonstrated that p-AKT is highly activated in many tumors, and its abnormal expression was shown to be closely related to tumor development and progression (<xref rid="b40-mmr-17-04-5764" ref-type="bibr">40</xref>). Members of caspase family are key elements in the process of apoptosis, and their activation and abnormal expression can induce apoptosis through the interaction with other factors (<xref rid="b41-mmr-17-04-5764" ref-type="bibr">41</xref>). Caspase-3 is the most important member of the caspase family involved in the process of apoptosis, mediating signaling triggered by many other molecules (<xref rid="b42-mmr-17-04-5764" ref-type="bibr">42</xref>). In the present study, the expression levels of p-AKT, BCL2, and caspase-3 were shown to differ between the cells overexpressing <italic>MDA7/IL24</italic> and the controls, indicating that MDA7/IL24 can inhibit tumor progression by inducing apoptosis, which is consistent with the results of cell functional experiments.</p>
<p>Taken together, our results demonstrate that MDA7/IL24 can inhibit the proliferation and suppress tumorigenicity of HCC cells <italic>in vitro</italic>. Furthermore, the MDA7/IL24 exerts its effects through the regulation of cell cycle transition and the induction of apoptosis. Therefore, we demonstrated that MDA7/IL24 has anticancer functions, its overexpression inhibits HCC progression, and it may represent a novel therapeutic target for cancer treatment.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The present study was supported by the National Natural Science Foundation of China Youth Fund (81201673). The manuscript was edited and proofread by Editage.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="b1-mmr-17-04-5764"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>CJ</given-names></name><name><surname>Xiao</surname><given-names>CW</given-names></name><name><surname>You</surname><given-names>TG</given-names></name><name><surname>Zheng</surname><given-names>YX</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>ZQ</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>XB</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Interferon-&#x03B1; enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma</article-title><source>Mol Cancer</source><volume>11</volume><fpage>31</fpage><year>2012</year><pub-id pub-id-type="doi">10.1186/1476-4598-11-31</pub-id><pub-id pub-id-type="pmid">22569271</pub-id><pub-id pub-id-type="pmcid">3697897</pub-id></element-citation></ref>
<ref id="b2-mmr-17-04-5764"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>SH</given-names></name><name><surname>Guo</surname><given-names>WD</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>JP</given-names></name><name><surname>Cao</surname><given-names>YK</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells</article-title><source>World J Gastroenterol</source><volume>21</volume><fpage>9727</fpage><lpage>9735</lpage><year>2015</year><pub-id pub-id-type="doi">10.3748/wjg.v21.i33.9727</pub-id><pub-id pub-id-type="pmid">26361419</pub-id><pub-id pub-id-type="pmcid">4562956</pub-id></element-citation></ref>
<ref id="b3-mmr-17-04-5764"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Marrero</surname><given-names>JA</given-names></name><name><surname>Rudolph</surname><given-names>L</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name></person-group><article-title>Diagnosis and treatment of hepatocellular carcinoma</article-title><source>Gastroenterology</source><volume>134</volume><fpage>1752</fpage><lpage>1763</lpage><year>2008</year><pub-id pub-id-type="doi">10.1053/j.gastro.2008.02.090</pub-id><pub-id pub-id-type="pmid">18471552</pub-id></element-citation></ref>
<ref id="b4-mmr-17-04-5764"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name></person-group><article-title>Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo</article-title><source>Cancer Gene Ther</source><volume>17</volume><fpage>771</fpage><lpage>779</lpage><year>2010</year><pub-id pub-id-type="doi">10.1038/cgt.2010.34</pub-id><pub-id pub-id-type="pmid">20596089</pub-id><pub-id pub-id-type="pmcid">2963730</pub-id></element-citation></ref>
<ref id="b5-mmr-17-04-5764"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>CW</given-names></name><name><surname>Xue</surname><given-names>XB</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name></person-group><article-title>Oncolytic adenovirus-mediated MDA-7/IL-24 overexpression enhances antitumor activity in hepatocellular carcinoma cell lines</article-title><source>Hepatobiliary Pancreat Dis Int</source><volume>9</volume><fpage>615</fpage><lpage>621</lpage><year>2010</year><pub-id pub-id-type="pmid">21134831</pub-id></element-citation></ref>
<ref id="b6-mmr-17-04-5764"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>ZM</given-names></name><name><surname>Zhu</surname><given-names>XM</given-names></name><name><surname>Bao</surname><given-names>YM</given-names></name><name><surname>An</surname><given-names>LJ</given-names></name></person-group><article-title>MDA-7/IL-24 suppresses tumor adhesion and invasive potential in hepatocellular carcinoma cell lines</article-title><source>Oncol Rep</source><volume>30</volume><fpage>986</fpage><lpage>992</lpage><year>2013</year><pub-id pub-id-type="doi">10.3892/or.2013.2507</pub-id><pub-id pub-id-type="pmid">23722307</pub-id></element-citation></ref>
<ref id="b7-mmr-17-04-5764"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>JJ</given-names></name><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Goldstein</surname><given-names>NI</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression</article-title><source>Oncogene</source><volume>11</volume><fpage>2477</fpage><lpage>2486</lpage><year>1995</year><pub-id pub-id-type="pmid">8545104</pub-id></element-citation></ref>
<ref id="b8-mmr-17-04-5764"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>EY</given-names></name><name><surname>Madireddi</surname><given-names>MT</given-names></name><name><surname>Gopalkrishnan</surname><given-names>RV</given-names></name><name><surname>Leszczyniecka</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Lebedeva</surname><given-names>IV</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>JJ</given-names></name><name><surname>Alexandre</surname><given-names>D</given-names></name><etal/></person-group><article-title>Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppression and apoptosis inducing properties</article-title><source>Oncogene</source><volume>20</volume><fpage>7051</fpage><lpage>7063</lpage><year>2001</year><pub-id pub-id-type="doi">10.1038/sj.onc.1204897</pub-id><pub-id pub-id-type="pmid">11704829</pub-id></element-citation></ref>
<ref id="b9-mmr-17-04-5764"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellerhorst</surname><given-names>JA</given-names></name><name><surname>Prieto</surname><given-names>VG</given-names></name><name><surname>Ekmekcioglu</surname><given-names>S</given-names></name><name><surname>Broemeling</surname><given-names>L</given-names></name><name><surname>Yekell</surname><given-names>S</given-names></name><name><surname>Chada</surname><given-names>S</given-names></name><name><surname>Grimm</surname><given-names>EA</given-names></name></person-group><article-title>Loss of MDA7 expression with progression of melanoma</article-title><source>J Clin Oncol</source><volume>20</volume><fpage>1069</fpage><lpage>1074</lpage><year>2002</year><pub-id pub-id-type="doi">10.1200/JCO.2002.20.4.1069</pub-id><pub-id pub-id-type="pmid">11844832</pub-id></element-citation></ref>
<ref id="b10-mmr-17-04-5764"><label>10</label><element-citation publication-type="conference"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Vozhilla</surname><given-names>N</given-names></name><name><surname>Park</surname><given-names>ES</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>Dual cancer specific targeting strategy cures primary and distant breast carcinomas in nude mice</article-title><source>Proc Natl Acad Sci USA</source><volume>102</volume><fpage>14034</fpage><lpage>14039</lpage><conf-date>2005</conf-date><pub-id pub-id-type="doi">10.1073/pnas.0506837102</pub-id><pub-id pub-id-type="pmid">16172403</pub-id><pub-id pub-id-type="pmcid">1236587</pub-id></element-citation></ref>
<ref id="b11-mmr-17-04-5764"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caudell</surname><given-names>EG</given-names></name><name><surname>Mumm</surname><given-names>JB</given-names></name><name><surname>Poindexter</surname><given-names>N</given-names></name><name><surname>Ekmekcioglu</surname><given-names>S</given-names></name><name><surname>Mhashilkar</surname><given-names>AM</given-names></name><name><surname>Yang</surname><given-names>XH</given-names></name><name><surname>Retter</surname><given-names>MW</given-names></name><name><surname>Hill</surname><given-names>P</given-names></name><name><surname>Chada</surname><given-names>S</given-names></name><name><surname>Grimm</surname><given-names>EA</given-names></name></person-group><article-title>The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24</article-title><source>J Immunol</source><volume>168</volume><fpage>6041</fpage><lpage>6046</lpage><year>2002</year><pub-id pub-id-type="doi">10.4049/jimmunol.168.12.6041</pub-id><pub-id pub-id-type="pmid">12055212</pub-id></element-citation></ref>
<ref id="b12-mmr-17-04-5764"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>PB</given-names></name><name><surname>Gopalkrishnan</surname><given-names>RV</given-names></name><name><surname>Chada</surname><given-names>S</given-names></name><name><surname>Ramesh</surname><given-names>R</given-names></name><name><surname>Grimm</surname><given-names>EA</given-names></name><name><surname>Rosenfeld</surname><given-names>MR</given-names></name><name><surname>Curiel</surname><given-names>DT</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name></person-group><article-title>mda7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: From the laboratory into the clinic</article-title><source>Cancer Biol Ther</source><volume>2</volume><supplement>4 Suppl 1</supplement><fpage>S23</fpage><lpage>S37</lpage><year>2003</year><pub-id pub-id-type="doi">10.4161/cbt.458</pub-id><pub-id pub-id-type="pmid">14508078</pub-id></element-citation></ref>
<ref id="b13-mmr-17-04-5764"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>AW</given-names></name><name><surname>Nemunaitis</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name><name><surname>Senzer</surname><given-names>N</given-names></name><name><surname>Netto</surname><given-names>G</given-names></name><name><surname>Rich</surname><given-names>D</given-names></name><name><surname>Mhashilkar</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>K</given-names></name><etal/></person-group><article-title>Intratumoral injection of INGN 241, a nonreolicating adenovector expressing the melanoma-differentiation associated gene-7 (mda7/IL-24): Biologic outcome in advanced cancer patients</article-title><source>Mol Ther</source><volume>11</volume><fpage>160</fpage><lpage>172</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.ymthe.2004.09.021</pub-id><pub-id pub-id-type="pmid">15585417</pub-id></element-citation></ref>
<ref id="b14-mmr-17-04-5764"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebedeva</surname><given-names>IV</given-names></name><name><surname>Sauane</surname><given-names>M</given-names></name><name><surname>Gopalkrishnan</surname><given-names>RV</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Nemunaitis</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name><name><surname>Yacoub</surname><given-names>A</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>Mda7/IL-24: Exploiting cancer&#x0027;s Achilles&#x0027; heel</article-title><source>Mol Ther</source><volume>11</volume><fpage>4</fpage><lpage>18</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.ymthe.2004.08.012</pub-id><pub-id pub-id-type="pmid">15585401</pub-id></element-citation></ref>
<ref id="b15-mmr-17-04-5764"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Sha</surname><given-names>Y</given-names></name></person-group><article-title>RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation ability, promotesapoptosis of human melanoma cells</article-title><source>J Dermatol Sci</source><volume>79</volume><fpage>57</fpage><lpage>63</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.jdermsci.2015.03.020</pub-id><pub-id pub-id-type="pmid">25920913</pub-id></element-citation></ref>
<ref id="b16-mmr-17-04-5764"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diao</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hao</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Loss of diacylglycerol kinase-&#x0396; inhibits cell proliferation and survival in human gliomas</article-title><source>Mol Neurobiol</source><volume>53</volume><fpage>5425</fpage><lpage>5435</lpage><year>2016</year><pub-id pub-id-type="doi">10.1007/s12035-015-9419-4</pub-id><pub-id pub-id-type="pmid">26452358</pub-id></element-citation></ref>
<ref id="b17-mmr-17-04-5764"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>XB</given-names></name><name><surname>Xiao</surname><given-names>CW</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>AG</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>ZQ</given-names></name><name><surname>Guo</surname><given-names>XL</given-names></name><name><surname>Zhong</surname><given-names>MA</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>CJ</given-names></name></person-group><article-title>Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines</article-title><source>World J Gastroenterol</source><volume>16</volume><fpage>4677</fpage><lpage>4684</lpage><year>2010</year><pub-id pub-id-type="doi">10.3748/wjg.v16.i37.4677</pub-id><pub-id pub-id-type="pmid">20872968</pub-id><pub-id pub-id-type="pmcid">2951518</pub-id></element-citation></ref>
<ref id="b18-mmr-17-04-5764"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Adenovirus-mediated Il-24 expression suppresses hepatocellular carcinoma growth via induction of cell apoptosis and cycling arrest and reduction of angiogenesis</article-title><source>Cancer Biother Radiopharm</source><volume>22</volume><fpage>56</fpage><lpage>63</lpage><year>2007</year><pub-id pub-id-type="doi">10.1089/cbr.2006.370</pub-id><pub-id pub-id-type="pmid">17627414</pub-id></element-citation></ref>
<ref id="b19-mmr-17-04-5764"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emdad</surname><given-names>L</given-names></name><name><surname>Lebedeva</surname><given-names>IV</given-names></name><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Settleman</surname><given-names>J</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>Combinatorial treatment of non-small cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy</article-title><source>J Cell Physiol</source><volume>210</volume><fpage>549</fpage><lpage>559</lpage><year>2007</year><pub-id pub-id-type="doi">10.1002/jcp.20906</pub-id><pub-id pub-id-type="pmid">17111370</pub-id></element-citation></ref>
<ref id="b20-mmr-17-04-5764"><label>20</label><element-citation publication-type="conference"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Lebedeva</surname><given-names>IV</given-names></name><name><surname>Sauane</surname><given-names>M</given-names></name><name><surname>Gopalkrishnan</surname><given-names>RV</given-names></name><name><surname>Valerie</surname><given-names>K</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK</article-title><source>Proc Natl Acad Sci USA</source><volume>99</volume><fpage>10054</fpage><lpage>10059</lpage><conf-date>2002</conf-date><pub-id pub-id-type="doi">10.1073/pnas.152327199</pub-id><pub-id pub-id-type="pmid">12114539</pub-id><pub-id pub-id-type="pmcid">126623</pub-id></element-citation></ref>
<ref id="b21-mmr-17-04-5764"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenzie</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Fanale</surname><given-names>M</given-names></name><name><surname>Swisher</surname><given-names>SG</given-names></name><name><surname>Chada</surname><given-names>S</given-names></name><name><surname>Hunt</surname><given-names>KK</given-names></name></person-group><article-title>Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu-overexpressing breast cancer cells</article-title><source>Surgery</source><volume>136</volume><fpage>437</fpage><lpage>442</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.surg.2004.05.022</pub-id><pub-id pub-id-type="pmid">15300212</pub-id></element-citation></ref>
<ref id="b22-mmr-17-04-5764"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebedeva</surname><given-names>IV</given-names></name><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Gopalkrishnan</surname><given-names>RV</given-names></name><name><surname>Waxman</surname><given-names>S</given-names></name><name><surname>Yacoub</surname><given-names>A</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis</article-title><source>Oncogene</source><volume>24</volume><fpage>585</fpage><lpage>596</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/sj.onc.1208183</pub-id><pub-id pub-id-type="pmid">15580305</pub-id></element-citation></ref>
<ref id="b23-mmr-17-04-5764"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>LL</given-names></name><name><surname>Yuan</surname><given-names>CF</given-names></name><name><surname>Yang</surname><given-names>JX</given-names></name><name><surname>Yi</surname><given-names>FP</given-names></name><name><surname>Ma</surname><given-names>YP</given-names></name><name><surname>Song</surname><given-names>FZ</given-names></name></person-group><article-title>Melanoma differentiation-associated gene-7/interleukin 24 inhibits invasion and migration of human cervical cancer cells in vitro</article-title><source>Saudi Med J</source><volume>11</volume><fpage>1671</fpage><lpage>1675</lpage><year>2007</year></element-citation></ref>
<ref id="b24-mmr-17-04-5764"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menezes</surname><given-names>ME</given-names></name><name><surname>Shen</surname><given-names>XN</given-names></name><name><surname>Das</surname><given-names>SK</given-names></name><name><surname>Emdad</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Archer</surname><given-names>MC</given-names></name><name><surname>Zacksenhaus</surname><given-names>E</given-names></name><name><surname>Windle</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer</article-title><source>Oncotarget</source><volume>6</volume><fpage>36928</fpage><lpage>36942</lpage><year>2015</year><pub-id pub-id-type="doi">10.18632/oncotarget.6047</pub-id><pub-id pub-id-type="pmid">26474456</pub-id><pub-id pub-id-type="pmcid">4741906</pub-id></element-citation></ref>
<ref id="b25-mmr-17-04-5764"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Miyahara</surname><given-names>R</given-names></name><name><surname>Gopalan</surname><given-names>B</given-names></name><name><surname>Litvak</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name><name><surname>Shanker</surname><given-names>M</given-names></name><name><surname>Branch</surname><given-names>CD</given-names></name><name><surname>Mhashilkar</surname><given-names>AM</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Chada</surname><given-names>S</given-names></name><name><surname>Ramesh</surname><given-names>R</given-names></name></person-group><article-title>Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation associated-7 (mda-7)/interleukin-24 (IL-24) gene</article-title><source>Cancer Gene Ther</source><volume>12</volume><fpage>238</fpage><lpage>247</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/sj.cgt.7700811</pub-id><pub-id pub-id-type="pmid">15578066</pub-id></element-citation></ref>
<ref id="b26-mmr-17-04-5764"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawabe</surname><given-names>S</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name><name><surname>Munshi</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Chada</surname><given-names>S</given-names></name><name><surname>Meyn</surname><given-names>RE</given-names></name></person-group><article-title>Adenovirus-mediated mda-7 gene expression radiosensitizes non-small cell lung cancer cells via TP53-independent mechanisms</article-title><source>Mol Ther</source><volume>6</volume><fpage>637</fpage><lpage>644</lpage><year>2002</year><pub-id pub-id-type="doi">10.1006/mthe.2002.0714</pub-id><pub-id pub-id-type="pmid">12409262</pub-id></element-citation></ref>
<ref id="b27-mmr-17-04-5764"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauane</surname><given-names>M</given-names></name><name><surname>Gopalkrishnan</surname><given-names>RV</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Lebedeva</surname><given-names>IV</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Pestka</surname><given-names>S</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>MDA-7/IL-24: Novel cancer growth suppressing and apoptosis inducing cytokine</article-title><source>Cytokine Growth Factor Rev</source><volume>14</volume><fpage>35</fpage><lpage>51</lpage><year>2003</year><pub-id pub-id-type="doi">10.1016/S1359-6101(02)00074-6</pub-id><pub-id pub-id-type="pmid">12485618</pub-id></element-citation></ref>
<ref id="b28-mmr-17-04-5764"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauane</surname><given-names>M</given-names></name><name><surname>Gopalkrishnan</surname><given-names>RV</given-names></name><name><surname>Lebedeva</surname><given-names>I</given-names></name><name><surname>Mei</surname><given-names>MX</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Kang</surname><given-names>DC</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Pestka</surname><given-names>S</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways</article-title><source>J Cell Physiol</source><volume>196</volume><fpage>334</fpage><lpage>345</lpage><year>2003</year><pub-id pub-id-type="doi">10.1002/jcp.10309</pub-id><pub-id pub-id-type="pmid">12811827</pub-id></element-citation></ref>
<ref id="b29-mmr-17-04-5764"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Lebedeva</surname><given-names>IV</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Gopalkrishnan</surname><given-names>RV</given-names></name><name><surname>Sauane</surname><given-names>M</given-names></name><name><surname>Sigmon</surname><given-names>C</given-names></name><name><surname>Yacoub</surname><given-names>A</given-names></name><name><surname>Valerie</surname><given-names>K</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner</article-title><source>Oncogene</source><volume>22</volume><fpage>1164</fpage><lpage>1180</lpage><year>2003</year><pub-id pub-id-type="doi">10.1038/sj.onc.1206062</pub-id><pub-id pub-id-type="pmid">12606943</pub-id></element-citation></ref>
<ref id="b30-mmr-17-04-5764"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>ZZ</given-names></name><name><surname>Lebedeva</surname><given-names>IV</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Emdad</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Kitada</surname><given-names>S</given-names></name><name><surname>Dent</surname><given-names>P</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name><name><surname>Fisher</surname><given-names>PB</given-names></name></person-group><article-title>Ionizing radiation enhances therapeutic activity of mda-7/IL-24: Overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2</article-title><source>Oncogene</source><volume>25</volume><fpage>2339</fpage><lpage>2348</lpage><year>2006</year><pub-id pub-id-type="doi">10.1038/sj.onc.1209271</pub-id><pub-id pub-id-type="pmid">16331261</pub-id></element-citation></ref>
<ref id="b31-mmr-17-04-5764"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara</surname><given-names>I</given-names></name><name><surname>Miyake</surname><given-names>K</given-names></name><name><surname>Hanawa</surname><given-names>H</given-names></name><name><surname>Kurai</surname><given-names>T</given-names></name><name><surname>Hirai</surname><given-names>Y</given-names></name><name><surname>Ishizaki</surname><given-names>M</given-names></name><name><surname>Uchida</surname><given-names>E</given-names></name><name><surname>Tajiri</surname><given-names>T</given-names></name><name><surname>Shimada</surname><given-names>T</given-names></name></person-group><article-title>Systemic cancer gene therapy using adeno-associated virus type 1 vector expressing MDA-7/IL24</article-title><source>Mol Ther</source><volume>15</volume><fpage>1805</fpage><lpage>1811</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/sj.mt.6300225</pub-id><pub-id pub-id-type="pmid">17551500</pub-id></element-citation></ref>
<ref id="b32-mmr-17-04-5764"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name></person-group><article-title>MicroRNA-25 regulates small cell lung cancer cell development and cell cycle through cyclin E2</article-title><source>Int J Clin Exp Pathol</source><volume>7</volume><fpage>7726</fpage><lpage>7734</lpage><year>2014</year><pub-id pub-id-type="pmid">25550809</pub-id><pub-id pub-id-type="pmcid">4270611</pub-id></element-citation></ref>
<ref id="b33-mmr-17-04-5764"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name></person-group><article-title>Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition</article-title><source>Oncotarget</source><volume>17</volume><fpage>23767</fpage><lpage>23771</lpage><year>2016</year></element-citation></ref>
<ref id="b34-mmr-17-04-5764"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>HC</given-names></name><name><surname>Clurman</surname><given-names>BE</given-names></name></person-group><article-title>Cyclin E in normal and neoplastic cell cycles</article-title><source>Oncogene</source><volume>24</volume><fpage>2776</fpage><lpage>2786</lpage><year>2005</year><pub-id pub-id-type="doi">10.1038/sj.onc.1208613</pub-id><pub-id pub-id-type="pmid">15838514</pub-id></element-citation></ref>
<ref id="b35-mmr-17-04-5764"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Qiu</surname><given-names>ZX</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>WM</given-names></name></person-group><article-title>Prognostic values of ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer</article-title><source>Tumor Biol</source><volume>36</volume><fpage>4143</fpage><lpage>4150</lpage><year>2015</year><pub-id pub-id-type="doi">10.1007/s13277-015-3048-4</pub-id></element-citation></ref>
<ref id="b36-mmr-17-04-5764"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations</article-title><source>J Exp Clin Cancer Res</source><volume>28</volume><fpage>65</fpage><year>2009</year><pub-id pub-id-type="doi">10.1186/1756-9966-28-65</pub-id><pub-id pub-id-type="pmid">19445727</pub-id><pub-id pub-id-type="pmcid">2691734</pub-id></element-citation></ref>
<ref id="b37-mmr-17-04-5764"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabokrouh</surname><given-names>A</given-names></name><name><surname>Vaisi-Raygani</surname><given-names>A</given-names></name><name><surname>Goodarzi</surname><given-names>MT</given-names></name><name><surname>Khatami</surname><given-names>S</given-names></name><name><surname>Taghizadeh-Jahed</surname><given-names>M</given-names></name><name><surname>Shahabadi</surname><given-names>N</given-names></name><name><surname>Lakpour</surname><given-names>N</given-names></name><name><surname>Shakiba</surname><given-names>Y</given-names></name></person-group><article-title>Comparison between platinum-azidothymidine and azidothymidine effects on Bcl-2 and telomerase gene expression in rats with hepatocellular carcinoma</article-title><source>Avicenna J Med Biotech</source><volume>7</volume><fpage>50</fpage><lpage>56</lpage><year>2015</year></element-citation></ref>
<ref id="b38-mmr-17-04-5764"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>N</given-names></name><name><surname>Sun</surname><given-names>BC</given-names></name><name><surname>Zhao</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Che</surname><given-names>N</given-names></name><name><surname>Dong</surname><given-names>XY</given-names></name><name><surname>Gu</surname><given-names>Q</given-names></name></person-group><article-title>Role of Bcl-2 and its associated miRNAs in vasculogenic mimicry of hepatocellular carcinoma</article-title><source>Int J Clin Exp Pathol</source><volume>8</volume><fpage>15759</fpage><lpage>15768</lpage><year>2015</year><pub-id pub-id-type="pmid">26884845</pub-id><pub-id pub-id-type="pmcid">4730058</pub-id></element-citation></ref>
<ref id="b39-mmr-17-04-5764"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correia</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Meng</surname><given-names>XW</given-names></name><name><surname>Vincelette</surname><given-names>ND</given-names></name><name><surname>Knorr</surname><given-names>KL</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>Nowakowski</surname><given-names>GS</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name></person-group><article-title>Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment</article-title><source>Biochim Biophys Acta</source><volume>1853</volume><fpage>1658</fpage><lpage>1671</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.bbamcr.2015.03.012</pub-id><pub-id pub-id-type="pmid">25827952</pub-id><pub-id pub-id-type="pmcid">4429517</pub-id></element-citation></ref>
<ref id="b40-mmr-17-04-5764"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>LF</given-names></name><name><surname>Ni</surname><given-names>JY</given-names></name><name><surname>Sun</surname><given-names>HL</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Wu</surname><given-names>YD</given-names></name></person-group><article-title>Effects of hypoxia-inducible factor-1&#x03B1; silencing on the proliferation of CBRH-7919 hepatoma cells</article-title><source>World J Gastroenterol</source><volume>19</volume><fpage>1749</fpage><lpage>1759</lpage><year>2013</year><pub-id pub-id-type="doi">10.3748/wjg.v19.i11.1749</pub-id><pub-id pub-id-type="pmid">23555163</pub-id><pub-id pub-id-type="pmcid">3607751</pub-id></element-citation></ref>
<ref id="b41-mmr-17-04-5764"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>RW</given-names></name><name><surname>Elliott</surname><given-names>BT</given-names></name></person-group><article-title>Akt/PKB activation and insulin signaling: A novel insulin signaling pathway in the treatment of type 2 diabetes</article-title><source>Diabetes Metab Syndr Obes</source><volume>7</volume><fpage>55</fpage><lpage>64</lpage><year>2014</year><pub-id pub-id-type="doi">10.2147/DMSO.S48260</pub-id><pub-id pub-id-type="pmid">24611020</pub-id><pub-id pub-id-type="pmcid">3928478</pub-id></element-citation></ref>
<ref id="b42-mmr-17-04-5764"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Fassan</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>HL</given-names></name><name><surname>Jeon</surname><given-names>YJ</given-names></name><name><surname>Vicentini</surname><given-names>C</given-names></name><name><surname>Tili</surname><given-names>E</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><etal/></person-group><article-title>MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7</article-title><source>Oncotarget</source><volume>6</volume><fpage>21802</fpage><lpage>21815</lpage><year>2015</year><pub-id pub-id-type="doi">10.18632/oncotarget.5224</pub-id><pub-id pub-id-type="pmid">26307684</pub-id><pub-id pub-id-type="pmcid">4673127</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mmr-17-04-5764" position="float">
<label>Figure 1.</label>
<caption><p>SMMC-7721 cells infected with LV-MDA7/IL24 or negative-control lentiviral particles. (A) Bright-field and fluorescent photomicrographs after the culturing of the infected cells for 3 days. Magnification, &#x00D7;100. (B) MDA7/IL24 mRNA expression levels in LV-MDA7/IL24-infected (OE) and negative control (NC) cells. Gene expression levels were normalized to that of the GAPDH. Data are presented as mean &#x00B1; SD obtained in three independent experiments (&#x002A;&#x002A;&#x002A;P&#x003C;0.001). LV-MDA7/IL24, lentiviral vector expressing MDA7/IL24; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g00.tif"/>
</fig>
<fig id="f2-mmr-17-04-5764" position="float">
<label>Figure 2.</label>
<caption><p>MDA7/IL24 protein expression in LV-MDA7/IL24-infected SMMC-7721 cells. (A) Western blot analysis indicated the protein expression of MDA7/IL24 in LV-MDA7/IL24-infected SMMC-7721 cells. (B) The densitometric and statistical analysis of western blot results in LV-MDA7/IL24-infected (OE), negative control (NC) and untreated cells (CON). Data are presented as mean &#x00B1; SD obtained in three independent experiments (&#x002A;&#x002A;&#x002A;P&#x003C;0.001). LV-MDA7/IL24, lentiviral vector expressing MDA7/IL24.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g01.tif"/>
</fig>
<fig id="f3-mmr-17-04-5764" position="float">
<label>Figure 3.</label>
<caption><p>MDA7/IL24 overexpression suppresses SMMC-7721 cell proliferation. (A) Cell proliferation of LV-MDA7/IL24-infected cell, negative control-infected cells, and untreated cells. (B and C) The photomicrographs of SMMC-7721 cells at different time points, including the fluorescent images of experimental group cells and the bright-field images of the control group cells. Magnification, &#x00D7;100. OE, cells infected with LV-MDA7/IL24; NC, cells infected with the negative control particles; CON, untreated cells.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g02.tif"/>
<graphic xlink:href="MMR-17-04-5764-g03.tif"/>
<graphic xlink:href="MMR-17-04-5764-g04.tif"/>
</fig>
<fig id="f4-mmr-17-04-5764" position="float">
<label>Figure 4.</label>
<caption><p>MDA7/IL24 overexpression reduces SMMC-7721 cell colony formation. (A) Colony formation assay results and crystal violet staining of SMMC-7721 colonies. (B) Quantification of cells in each colony. OE, cells infected with LV-MDA7/IL24; NC, cells infected with the negative control particles; CON, untreated cells. &#x002A;P&#x003C;0.05 as indicated.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g05.tif"/>
</fig>
<fig id="f5-mmr-17-04-5764" position="float">
<label>Figure 5.</label>
<caption><p>MDA7/IL24 overexpression induces SMMC-7721 cell apoptosis and cell cycle arrest. (A and B) The percentage of apoptosis cells in three different groups (&#x002A;P&#x003C;0.05). (C) The distribution of three groups of cells in the cell cycle (&#x002A;P&#x003C;0.05). OE, cells infected with LV-MDA7/IL24; NC, cells infected with the negative control particles; CON, untreated cells.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g06.tif"/>
</fig>
<fig id="f6-mmr-17-04-5764" position="float">
<label>Figure 6.</label>
<caption><p>MDA7/IL24 overexpression leads to changes in gene expression profile of SMMC-7721 cells. (A) Gene expression profiling results. Heatmap represents 43 genes shown to be differentially expressed between SMMC-7721 cells infected with negative-control (NC) lentivirus or LV-MDA7/IL24 (OE). Genes and samples are listed in rows and columns, respectively. Color scale: red represents gene expression upregulation; green, downregulation of gene expression. (B) Schematic representation of a network including MDA7/IL24 and genes involved in cell cycle regulation and apoptosis. Solid arrows, confirmed regulatory relationships; dotted lines, predicted regulatory relationships; T bars, inhibitory relationships.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g07.tif"/>
</fig>
<fig id="f7-mmr-17-04-5764" position="float">
<label>Figure 7.</label>
<caption><p>(A) Western blot analysis showing the expression levels of (B) AKT, (C) caspase-3 and (D) ERK1/2 in NC and OE cells. &#x002A;&#x002A;&#x002A;P&#x003C;0.001. ns, not significant; OE, cells infected with LV-MDA7/IL24; NC, cells infected with the negativecontrol particles; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g08.tif"/>
</fig>
<fig id="f8-mmr-17-04-5764" position="float">
<label>Figure 8.</label>
<caption><p>(A) Western blot analysis showing the expression levels of (B) p-AKT, (C) p-ERK1/2, (D) CCND1 in NC and OE cells. GAPDH was used as the loading control. &#x002A;P&#x003C;0.05; &#x002A;&#x002A;&#x002A;P&#x003C;0.001. ns, not significant. OE, cells infected with LV-MDA7/IL24; NC, cells infected with the negative control particles; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g09.tif"/>
</fig>
<fig id="f9-mmr-17-04-5764" position="float">
<label>Figure 9.</label>
<caption><p>(A) Western blot analysis showing the expression levels of (B) Bax, (C) CCNE2 and (D) CDK2 in NC and OE cells. GAPDH was used as the loading control. &#x002A;&#x002A;P&#x003C;0.01. ns, not significant; OE, cells infected with LV-MDA7/IL24; NC, cells infected with the negative control particles; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g10.tif"/>
</fig>
<fig id="f10-mmr-17-04-5764" position="float">
<label>Figure 10.</label>
<caption><p>(A) Western blot analysis showing the expression levels of and (B) C-PARP, (C) BCL2 and (D) PCNA in NC and OE cells. GAPDH was used as the loading control. &#x002A;&#x002A;&#x002A;P&#x003C;0.001. ns, not significant; OE, cells infected with LV-MDA7/IL24; NC, cells infected with the negative control particles; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.</p></caption>
<graphic xlink:href="MMR-17-04-5764-g11.tif"/>
</fig>
</floats-group>
</article>